BioNTech (NASDAQ:BNTX) Price Target Cut to $128.00 by Analysts at BMO Capital Markets

BioNTech (NASDAQ:BNTX) had its price target decreased by research analysts at BMO Capital Markets from $143.00 to $128.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price objective would suggest a potential upside of 38.57% from the company’s previous close.

Other equities analysts have also issued reports about the company. Truist Financial set a $155.00 target price on BioNTech in a research note on Tuesday. Leerink Partners lowered BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target on the stock. in a research note on Monday, February 2nd. Raymond James Financial restated an “outperform” rating on shares of BioNTech in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $140.00 price objective on shares of BioNTech in a report on Thursday, December 11th. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $135.38.

BioNTech Trading Up 10.1%

Shares of BioNTech stock traded up $8.48 during trading hours on Wednesday, reaching $92.37. 1,363,023 shares of the company’s stock were exchanged, compared to its average volume of 1,103,628. BioNTech has a 52-week low of $79.52 and a 52-week high of $124.00. The company has a fifty day moving average of $106.73 and a 200-day moving average of $102.83. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $20.80 billion, a price-to-earnings ratio of -35.11 and a beta of 1.51.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dodge & Cox grew its position in BioNTech by 315.7% during the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after acquiring an additional 2,769,654 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of BioNTech by 43.0% in the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after purchasing an additional 474,796 shares during the period. GSK plc acquired a new position in shares of BioNTech in the 4th quarter valued at about $84,711,000. Franklin Resources Inc. grew its holdings in shares of BioNTech by 76.8% during the 2nd quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock worth $80,065,000 after purchasing an additional 326,556 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of BioNTech by 5.6% during the 2nd quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock worth $72,517,000 after purchasing an additional 35,958 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Key Headlines Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Strong balance sheet and pipeline: BioNTech reported €17.2B in cash and securities and outlined six late‑stage readouts and multiple oncology programs that management says derisk execution and support long‑term value creation. BioNTech corporate update and results
• Positive Sentiment: Potential upside from the co‑founders’ new venture: BioNTech will receive a minority stake in the new company and may earn milestone payments and royalties from contributed rights/technologies, creating optionality if next‑gen mRNA assets succeed. Co‑founders launch new mRNA venture
• Neutral Sentiment: Mixed quarter — EPS beat but revenue dynamics weak: BioNTech beat EPS estimates (reported ($0.39) vs. ($0.57) expected) and posted revenue of $1.06B (above consensus), but revenue is down ~24% YoY and adjusted losses were reported. Investors will parse beats vs underlying growth trends. Q4 2025 earnings highlights
• Neutral Sentiment: Analyst repositioning: Jefferies cut its price target (from $151 to $138) but kept a buy rating — signaling some analyst confidence on long‑term upside despite nearer‑term risks. Analyst PT change
• Negative Sentiment: Cofounders’ exit raises governance and execution concerns: Founders Ugur Sahin and Özlem Türeci will leave by end‑2026 to start a new company; BioNTech will transfer certain rights/tech, prompting investor worry about talent loss and strategic disruption. Reuters: founders to leave
• Negative Sentiment: Weaker FY2026 revenue guidance: Management cut 2026 revenue guidance to roughly €2.0–2.3B (below Street expectations), increasing near‑term growth concerns and pressuring sentiment. Full results and guidance
• Negative Sentiment: Regulatory/legal overhang: A plaintiff firm (Johnson Fistel) is investigating potential claims against BioNTech’s executives, adding legal risk and headline volatility. Johnson Fistel investigation notice
• Negative Sentiment: Immediate market reaction: Multiple outlets report a steep intraday share decline after the combined news of the founder exit and weaker outlook, reflecting selling pressure and short‑term sentiment deterioration. Market reaction coverage

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.